

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-15. (Canceled)

16. (Withdrawn) A method of transplanting an organ, a tissue, or cells, the method comprising:

(a) administering to a donor:

(i) a pharmaceutical composition comprising nitric oxide; and

(ii) a second treatment selected from the group consisting of: inducing HO-1 in the donor; expressing HO-1 in the donor; inducing apoferritin in the donor; expressing apoferritin in the donor; and administering to the donor a pharmaceutical composition comprising HO-1, carbon monoxide, bilirubin, biliverdin, ferritin, iron, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, or apoferritin;

(b) obtaining an organ, a tissue, or cells from the donor; and

(c) transplanting the organ, tissue, or cells into a recipient, wherein the nitric oxide and second treatment administered in step (a) are sufficient to enhance survival or function of the organ, tissue, or cells after transplantation into the recipient.

17. (Withdrawn) A method of transplanting an organ, a tissue, or cells, the method comprising:

(a) providing an organ, tissue or cells of a donor;

(b) administering to the organ, tissue or cells ex vivo:

(i) a pharmaceutical composition comprising nitric oxide; and

(ii) a second treatment selected from the group consisting of: inducing HO-1 in the organ, tissue, or cells; expressing HO-1 in the organ, tissue, or cells; inducing ferritin in the organ, tissue, or cells; expressing ferritin in the organ, tissue, or cells; and administering to the organ, tissue or cells a pharmaceutical composition comprising HO 1, carbon monoxide, bilirubin, biliverdin, ferritin, iron, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, or apoferritin; and

(c) transplanting the organ, tissue or cells into a recipient, wherein the nitric oxide and second treatment administered to the organ, tissue, or cells in step (b) are sufficient to enhance survival or function of the organ, tissue or cells after transplantation.

18. (Currently amended) A method of transplanting an organ, a tissue, or cells, the method comprising:

- (a) providing [[an]] a whole organ, a tissue, or cells from a donor;
- (b) transplanting the organ, tissue, or cells into a recipient; and
- (c) before, during, or after step (b), administering to the recipient:

(i) a pharmaceutical composition comprising nitric oxide; and

(ii) a second treatment selected from the group consisting of: inducing HO-1 in the recipient; expressing HO-1 in the recipient; inducing apoferritin in the recipient; expressing apoferritin in the recipient; and administering to the recipient a pharmaceutical composition comprising HO-1, carbon monoxide, bilirubin, biliverdin, ferritin, iron, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, or apoferritin,

wherein the nitric oxide and second treatment administered to the recipient in step (c) is sufficient to enhance survival or function of the organ, tissue, or cells after transplantation of the organ, tissue, or cells to the recipient.

19. (Original) The method of claim 18, further comprising administering to the donor:

- (i) a pharmaceutical composition comprising nitric oxide; and

(ii) a second treatment selected from the group consisting of: inducing HO-1 in the donor; expressing HO-1 in the donor; inducing apoferritin in the donor; expressing apoferritin in the donor; and administering to the donor a pharmaceutical composition comprising HO-1, carbon monoxide, bilirubin, biliverdin, ferritin, iron, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, or apoferritin.

20. (Original) The method of claim 18, further comprising administering to the organ, tissue or cells ex vivo:

(i) a pharmaceutical composition comprising nitric oxide; and

(ii) a second treatment selected from the group consisting of: inducing HO-1 in the organ, tissue or cells; expressing HO-1 in the organ; inducing ferritin in the organ, tissue or cells; expressing ferritin in the organ, tissue or cells; and administering to the organ, tissue or cells a pharmaceutical composition comprising HO-1, carbon monoxide, bilirubin, biliverdin, ferritin, iron, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, or apoferritin.

21-23. (Canceled)

24. (Previously presented) The method of claim 18, wherein the pharmaceutical composition comprising nitric oxide and the second treatment are administered to the recipient before (b).

25. (Previously presented) The method of claim 18, wherein the pharmaceutical composition comprising nitric oxide and the second treatment are administered to the recipient during (b).

26. (Previously presented) The method of claim 18, wherein the pharmaceutical composition comprising nitric oxide and the second treatment are administered to the recipient after (b).

27. (Previously presented) The method of claim 18, wherein the pharmaceutical composition comprising nitric oxide and the second treatment are administered to the recipient before and during (b).

28. (Previously presented) The method of claim 18, wherein the pharmaceutical composition comprising nitric oxide and the second treatment are administered to the recipient before and after (b).

29. (Previously presented) The method of claim 18, wherein the pharmaceutical composition comprising nitric oxide and the second treatment are administered to the recipient before, during, and after (b).

30. (Currently amended) The method of claim 18, wherein ~~the pharmaceutical composition comprising nitric oxide and the second treatment are~~ is carbon monoxide and is administered to the recipient within 1 to 20 days after (b).

31-32. (Canceled)

33. (Previously presented) The method of claim 18, wherein the pharmaceutical composition comprising nitric oxide and the second treatment are administered to the recipient upon determination that the transplanted organ is undergoing or about to undergo chronic rejection.

34. (Previously presented) The method of claim 18, wherein the pharmaceutical composition comprising nitric oxide and the second treatment are administered to the recipient upon determination that the transplanted organ is undergoing or about to undergo acute rejection.

35. (Previously presented) The method of 19, wherein the donor is a live donor.

36. (Previously presented) The method of claim 19, wherein donor is a brain-dead donor.

37. (Previously presented) The method of claim 18, wherein the organ is a liver.

38. (Previously presented) The method of claim 18, wherein the organ is a kidney.

39. (Previously presented) The method of claim 18, wherein the organ is a heart.

40. (Previously presented) The method of claim 18, wherein the organ is a pancreas.

41. (Previously presented) The method of claim 18, wherein the organ is a lung.

42. (Previously presented) The method of claim 18, wherein the organ is a small intestine.

43. (Previously presented) The method of claim 18, wherein the organ is skin.

44. (Previously presented) The method of claim 18, wherein the donor is of a species different from that of the recipient.

45. (Previously presented) The method of claim 18, wherein the donor and the recipient are of the same species.